{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7916","pValueComment":"Two-sided p-value from log-rank test stratified by EGFR mutation group and race.","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.660","ciPctValue":"95","ciUpperLimit":"1.174","estimateComment":"Afatinib 40 mg-Pemetrexed/Cisplatin Chemotherapy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3850","paramType":"Hazard Ratio (HR)","paramValue":"0.880","statisticalComment":"Cox PH regression stratified by EGFR mutation group and race.","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.64","upperLimit":"33.58","value":"28.16"},{"groupId":"OG001","lowerLimit":"20.73","upperLimit":"33.22","value":"28.22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"OS was defined as time from randomisation to death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Afatinib monotherapy 40 mg film-coated tablets orally once daily.","id":"OG000","title":"Afatinib 40 mg"},{"description":"Patients received Pemetrexed 500 mg/m\\^2 lyophilised powder as intravenous infusion after Cisplatin 75 mg/m\\^2 solution for infusion as intravenous infusion on Day 1 of each 21-day treatment course up to 6 cycles.","id":"OG001","title":"Pemetrexed/Cisplatin Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"RS.","reportingStatus":"POSTED","timeFrame":"From randomisation to cut-off date (17MAR2017).","title":"Overall Survival (OS) Time","type":"SECONDARY","unitOfMeasure":"Months."}